

Module: QScript Learning –Gabapentinoids

Course: PRESCRIBER AND DISPENSER TRAINING

Suggested Citation:

Insight: Centre for AOD Training and Workforce Development. Gabapentinoids. QScript Learning. Prescriber and dispenser training [Internet]. 2023. Available from: <https://insight.qld.edu.au/training/elearning>.

1. NPS Medicinewise. Gabapentinoid misuse: an emerging problem Surry Hills, NSW: NPS Medicinewise; 2018 [cited 2020 21 January]. Available from: <https://www.nps.org.au/news/gabapentinoid-misuse-an-emerging-problem>.
2. Cairns R, Schaffer AL, Ryan N, Pearson SA, Buckley NA. Rising pregabalin use and misuse in Australia: trends in utilization and intentional poisonings. *Addiction*. 2019;114(6):1026-34.doi: 10.1111/add.14412
3. Goodman CW, Brett AS. Gabapentinoids for Pain: Potential Unintended Consequences. *American family physician* [Internet]. 2019 [cited 2020 30/01]; 100(11):[672-5 pp.]. Available from: <https://www.aafp.org/afp/2019/1201/p672.html>.
4. Goodman CW, Brett AS. A Clinical Overview of Off-label Use of Gabapentinoid Drugs. *JAMA internal medicine*. 2019;179(5):695.doi: 10.1001/jamainternmed.2019.0086
5. Murnion B, Schaffer A, Cairns R, Brett J. Gabapentinoids: repeating mistakes of the past? *Addiction*. 2022;117(12):2969-71.doi: <https://doi.org/10.1111/add.15970>
6. Rigby D. Medication in review: Pain management with gabapentinoids: Benefits and harms. *AJP*. 2018;99(1169):68-71.doi:
7. National Health Service UK. Advice for prescribers on the risk of the misuse of pregabalin and gabapentin. United Kingdom: Public health Engalnd, NHS England; 2014 [cited 2020 4 February]. Available from: <https://www.gov.uk/government/publications/pregabalin-and-gabapentin-advice-for-prescribers-on-the-risk-of-misuse>.
8. Neurology Expert Group. Therapeutic guidelines: Neuropathic Pain West Melbourne, VIC: Therapeutic Guidelines Ltd; 2014 [cited 2020 21 January]. Available from: <https://tgldcdp.tg.org.au/viewTopic?topicfile=neuropathic-pain>.
9. Peckham AM, Evoy KE, Ochs L, Covvey JR. Gabapentin for off-label use: evidence-based or cause for concern? *Subst Abuse*. 2018;12:1178-2218.doi: 10.1177/1178221818801311
10. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part C2: The role of opioids in pain management Melbourne: RACGP; 2017 [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
11. Lewin E. Australia's overdose crisis is 'getting worse': Royal Australian College of General Practitioners; 2019 [cited 2020 28 Sep]. Available from: <https://www1.racgp.org.au/newsgp/clinical/australia-s-overdose-crisis-is-getting-worse>.
12. Makdessi CJ, Day C, Char BB. Challenges faced with opioid prescriptions in the community setting – Australian pharmacists' perspectives. *Research in Social and Administrative Pharmacy*. 2019;15(8):966-73.doi: 10.1016/j.sapharm.2019.01.017
13. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice, Part A – Clinical governance framework Melbourne: RACGP; 2015 [cited 2019 Aug 1]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
14. Hoppe D, Ristevski E, Khalil H. The attitudes and practice strategies of community pharmacists towards drug misuse management: A scoping review. *Journal of clinical pharmacy and therapeutics*. 2020;45(3):430-52.doi: 10.1111/jcpt.13100
15. Nielsen S, Kowalski M, Wood P, Larney S, Bruno R, Shanahan M, et al. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. *Research in Social and Administrative Pharmacy*. 2019;15(8):1047-55.doi: 10.1016/j.sapharm.2018.10.024

16. Therapeutic Goods Administration. Advisory Committee on Medicines Meeting statement – Meeting 13, Friday 1 February 2019 Woden, ACT: Australian Government, Department of Health; 2019 [cited 2020 21 January]. Available from: <https://www.tga.gov.au/sites/default/files/acm-meeting-statement-meeting-13-1-february-2019.pdf>.
17. International Association for the Study of Pain. Neuropathic Pain Washington, DC: IASP; 2017 [cited 2020 26/02]. Available from: <https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Neuropathicpain>.
18. Scholz J, Finnerup NB, Attal N, Aziz Q, Baron R, Bennett MI, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. *Pain*. 2019;160(1):53-9.doi: 10.1097/j.pain.0000000000001365
19. Insight Centre for AOD Training and Workforce Development, QScript Learning. Dr Ian Thong - Diagnosing neuropathic pain 2020 [cited 2020 20 Sep]. Available from: <https://youtu.be/rUHVPzvYBAs>.
20. Therapeutic Guidelines Limited. Pain and analgesia eTG complete2014 [cited 2020 4 Oct]. Available from: <https://www.tg.org.au>.
21. Chaparro LE, Wiffen PJ, Moore RA, Gilron I. Combination pharmacotherapy for the treatment of neuropathic pain in adults. *Cochrane Pain, Palliative and Supportive Care Group*. 2020;2017(7).doi: 10.1002/14651858.CD008943.pub2
22. Insight Centre for AOD Training and Workforce Development, QScript Learning. Dr Ian Thong - Treatment of neuropathic pain 2020 [cited 2020 20 Sep]. Available from: https://youtu.be/O8D_Em9gO9Q.
23. Insight Centre for AOD Training and Workforce Development, QScript Learning. Prescribing for a one off encounter an inherited patient from your own practice- Lisa Barling 2020 [cited 2020 20 Sep]. Available from: <https://youtu.be/Y8yaie7XpBk>.
24. Goodman CW, Brett AS. Gabapentin and Pregabalin for Pain — Is Increased Prescribing a Cause for Concern? *New England Journal of Medicine*. 2017;377(5):411-4.doi: 10.1056/nejmp1704633
25. Onakpoya IJ, Thomas ET, Lee JJ, Goldacre B, Heneghan CJ. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. *BMJ Open*. 2019;9(1):e023600.doi: 10.1136/bmjopen-2018-023600
26. Insight Centre for AOD Training and Workforce Development, QScript Learning. Dr Ian Thong - Gabapentinoids in fibromyalgia and complex regional pain syndrome 2020 [cited 2020 20 Sep]. Available from: https://youtu.be/X6_iUw8xhlc.
27. Morrison EE, Sandilands EA, Webb DJ. Gabapentin and pregabalin: do the benefits outweigh the harms? *J R Coll Physicians Edinb*. 2017;47(4):310-3.doi: 10.4997/jrcpe.2017.402
28. Nugraha B, Gutenbrunner C, Barke A, Karst M, Schiller J, Schäfer P, et al. The IASP classification of chronic pain for ICD-11: functioning properties of chronic pain. *Pain*. 2019;160(1):88-94.doi: 10.1097/j.pain.0000000000001433
29. Wiffen P, Derry S, Bell R, Rice A, Toelle T, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. *Cochrane Database of Systematic Reviews*. 2017;6:CD007938.doi: 10.1002/14651858.CD007938.pub4
30. Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. *Cochrane Database of Systematic Reviews*. 2019.doi: 10.1002/14651858.cd007076.pub3
31. Insight Centre for AOD Training and Workforce Development, QScript Learning. Dr Steve Gilbert - Gabapentinoids, neuropathic and nociplastic pain 2020 [cited 2020 20 Sep]. Available from: https://youtu.be/7LFabbf_Zlk.
32. Berlin RK, Butler PM, Perloff MD. Gabapentin therapy in psychiatric disorders: A systematic review. *Prim Care Companion CNS Disord*. 2015;17(5):10.4088/PCC.15r01821.doi: 10.4088/PCC.15r01821
33. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis. *International Clinical Psychopharmacology*. 2017;32(1):49-55.doi: 10.1097/YIC.000000000000147
34. Anderson H, Daly S. Are gabapentin-related medications effective in reducing anxiety symptoms in adults with anxiety disorders? *Evidence-Based Practice [Internet]*. 2019 [cited 2020 04/02]; 22(10):[18-9 pp.]. Available from: https://journals.lww.com/ebp/Citation/2019/10000/Are_gabapentin_related_medications_effective_in.17.aspx.
35. Ahmed S, Bachu R, Kotapati P, Adnan M, Ahmed R, Farooq U, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. *Frontiers in Psychiatry*. 2019;10.doi: 10.3389/fpsy.2019.00228

36. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. *Dialogues in clinical neuroscience*. 2017;19(2):93-107.doi: 10.31887/DCNS.2017.19.2/bbandelow
37. Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. *Neuropsychiatric disease and treatment*. 2013;9:883-92.doi: 10.2147/NDT.S36453
38. Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. *Australian & New Zealand Journal of Psychiatry*. 2018;52(12):1109-72.doi: 10.1177/0004867418799453
39. Royal Australian College of General Practitioners. Prescribing drugs of dependence in general practice - Part C1: Opioids Melbourne: RACGP; 2017 [cited 2019 Mar 21]. Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/drugs-of-dependence>.
40. Hall T, Shah S, Ng B, Feberwee H, Dotchin L, Vandermost M, et al. Changes in mood, depression and suicidal ideation after commencing pregabalin for neuropathic pain. *Australian Family Physician*. 2014;43:705-8.doi: 10.1177/2042098613505614
41. Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, Dombrowski R, et al. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *Journal of the American Geriatrics Society*. 2019;67(4):674-94.doi: 10.1111/jgs.15767
42. NPS MedicineWise. Pregabalin (Lyrica) for neuropathic pain 2013 [cited 2020 30 Sep]. Available from: <https://www.nps.org.au/radar/articles/pregabalin-lyrica-for-neuropathic-pain#references>.
43. Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. *Therapeutic Advances in Drug Safety*. 2014;5(1):38-56.doi: 10.1177/2042098613505614
44. Ho JM, Tricco AC, Perrier L, Chen M, Juurlink DN, Straus SE. Risk of heart failure and edema associated with the use of pregabalin: a systematic review. *Systematic reviews*. 2013;2:25-.doi: 10.1186/2046-4053-2-25
45. Finegan A, Mabrouk U, Nelson LA. Gabapentin-induced bilateral lower extremity edema in a patient with pervasive developmental disorder and schizoaffective disorder. *The mental health clinician*. 2020;10(4):250.doi: 10.9740/mhc.2020.07.250
46. Gallagher R, Apostle N. Peripheral edema with pregabalin. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2013;185(10):E506-E.doi: 10.1503/cmaj.121232
47. King MA. Pregabalin and gabapentin associated with depression and suicidal ideation. *BMJ*. 2018;363:k4979.doi: 10.1136/bmj.k4979
48. Therapeutic Goods Administration. APO-Pregabalin. Product Information - Australia [Internet]. 2021 [cited 2023 30 Jan]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2021-PI-01695-1>.
49. Therapeutic Goods Administration. Australian Product Information - Gabapentin Sandoz® (Gabapentin) Capsules Product Information - Australia [Internet]. 2023 [cited 2023 30 Jan]. Available from: <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04233-3&d=20230130172310101>.
50. Department of Veterans' Affairs. Reviewing your patients on gabapentinoids [cited 2021 3 Mar]. Available from: <https://www.veteransmates.net.au/topic-58-therapeutic-brief>.
51. Australian Medicines Handbook. Australian medicines handbook 2019. Buckley N, editor. Adelaide, SA: Australian Medicines Handbook; 2019.
52. Shanthanna H, Gilron I, Rajarathinam M, AlAmri R, Kamath S, Thabane L, et al. Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials. *PLoS Med*. 2017;14(8):e1002369.doi: 10.1371/journal.pmed.1002369
53. Parsons G. Guide to the management of gabapentinoid misuse. *Prescriber*. 2018;29(4):25-30.doi: 10.1002/psb.1664
54. Lyrica: MIMS Australia; 2019 [cited 2021 7 March]. Available from: <http://www.mims.com.au>.
55. Gabapentin: MIMS Australia; 2019 [cited 2020 24 January]. Available from: <http://www.mims.com.au>.
56. Insight Centre for AOD Training and Workforce Development, QScript Learning. Initiating gabapentinoids- Dr Geraldine Chew 2020 [cited 2020 20 Sep]. Available from: <https://youtu.be/hV9SfUw-bsU>.
57. Evoy K, Morrison M, Saklad S. Abuse and misuse of pregabalin and gabapentin. *Drugs*. 2017;77(4):403-26.doi: 10.1007/s40265-017-0700-x

58. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study. *PLoS Med.* 2017;14(10):e1002396-e.doi: 10.1371/journal.pmed.1002396

59. Insight Centre for AOD Training and Workforce Development, QScript Learning. Precautions when initiating gabapentinoids- Dr Geraldine Chew 2020 [cited 2020 20 Sep]. Available from: <https://youtu.be/QI-Q0ULQVvk>.